STOCK TITAN
  1. Home
  2. Sec-filings
  3. MREO
  4. [8-K] Mereo BioPharma Group plc Reports Material Event

Mereo BioPharma (NASDAQ: MREO) gains investor approval for pay and share issuance powers

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Mereo BioPharma Group plc reported the results of its 2026 Annual General Meeting, where all resolutions passed. Shareholder turnout was high, with 436,766,255 ordinary shares represented in person or by proxy.

Shareholders adopted the annual report and accounts for the year ended December 31, 2025, with 98.29% of votes cast in favor, and re-appointed PricewaterhouseCoopers LLP as auditors with 98.59% support. The Audit and Risk Committee was authorized to determine PwC’s remuneration.

Investors approved the directors’ remuneration report with 93.35% support and the directors’ remuneration policy, effective after the AGM, with 91.74% support. The compensation of named executive officers received 91.71% advisory approval. Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were each re-elected as directors, receiving around 94% of votes cast.

Shareholders also authorized the directors to allot shares and grant rights to subscribe or convert up to a maximum nominal amount of £3,591,354.73, and to do so on a non-pre-emptive basis, both authorities running until June 30, 2029. These replace earlier share issuance authorities to the extent not already used.

Positive

  • None.

Negative

  • None.

Insights

Routine AGM approvals, including renewed equity issuance authority, with strong but not unanimous support.

Mereo BioPharma secured broad shareholder backing for its 2025 accounts, auditor re-appointment, pay resolutions and board re-elections. Support levels in the low-to-mid 90% range for most governance items indicate overall alignment, though some investors expressed dissent on remuneration and capital authorities.

Resolutions 10 and 11 give directors authority to allot shares and issue for cash on a non-pre-emptive basis up to a nominal £3,591,354.73 until June 30, 2029, each passing with about 80% support. This increases flexibility to raise equity or structure transactions without pre-emptive rights, while the meaningful minority against highlights some sensitivity around potential dilution.

Because the filing does not quantify how this nominal limit compares with current share capital, the economic scale of the authority is not fully clear from the excerpt alone. Future capital raising decisions under these powers, if any, would determine the real impact on existing holders, but the vote itself is a standard governance step.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Shares represented at AGM 436,766,255 shares Ordinary shares entitled to vote represented in person or by proxy
Support for 2025 accounts 311,388,645 votes (98.29%) Votes for adoption of annual report and accounts for year ended December 31, 2025
Auditor re-appointment support 429,804,470 votes (98.59%) Votes for re-appointment of PricewaterhouseCoopers LLP as auditors
Directors’ pay policy support 290,456,675 votes (91.74%) Votes for directors’ remuneration policy effective after the AGM
Say-on-pay support 290,149,130 votes (91.71%) Advisory approval of named executive officer compensation
Authority to allot shares £3,591,354.73 nominal Maximum nominal amount for share allotment and non-pre-emptive issues until June 30, 2029
Support for share allotment authority 254,728,730 votes (80.54%) Votes for Resolution 10 authorizing directors to allot shares
Annual General Meeting financial
"held its 2026 Annual General Meeting of Shareholders (the “AGM”)"
directors’ remuneration policy financial
"That the directors’ remuneration policy as set out in the Company’s annual report"
non-pre-emptive basis financial
"authorized to allot shares for cash on a non-pre-emptive basis up to a maximum nominal amount"
Companies Act 2006 regulatory
"authorized in accordance with section 551 of the Companies Act 2006 to allot shares"
named executive officers financial
"That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis."
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
Understanding 8-K Material Events →
0001719714truefalseX000-000000000017197142026-05-142026-05-140001719714dei:AdrMember2026-05-142026-05-140001719714us-gaap:CommonStockMember2026-05-142026-05-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 14, 2026

 

MEREO BIOPHARMA GROUP PLC

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

England and Wales

 

001-38452

 

Not Applicable

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

4th Floor, One Cavendish Place,

London, W1G 0QF

United Kingdom

(Address of principal executive offices, including zip code)

 

+44-333-023-7300

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which
registered

American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share

 

MREO

 

The Nasdaq Stock Market LLC

Ordinary Shares, nominal value £0.003 per share*

 

*

 

The Nasdaq Stock Market LLC


*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 14, 2026, Mereo BioPharma Group plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 436,766,255 ordinary shares represented in person or by proxy at the AGM. The matters voted upon at the AGM, and the final results of such voting are set forth below. A “vote withheld” is not a vote in law and votes withheld had no effect on the proposals.

 

Resolution 1

 

That the annual report and accounts for the year ended December 31, 2025, together with the directors’ report and independent auditor’s report thereon, be received and adopted.

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

311,388,645

 

98.29%

 

5,412,060

 

1.71%

 

119,965,550

Resolution 2

That PricewaterhouseCoopers LLP (“PwC”) be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company’s annual report and accounts are presented.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

429,804,470

 

98.59%

 

6,156,620

 

1.41%

 

805,165

 

Resolution 3

That the Audit and Risk Committee be authorized to determine PwC’s remuneration for the fiscal year ending December 31, 2026.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

311,313,685

 

98.22%

 

5,656,600

 

1.78%

 

119,795,970

 

Resolution 4

That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the year ended December 31, 2025, be approved.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

295,564,225

 

93.35%

 

21,038,465

 

6.65%

 

120,163,565

 

Resolution 5

That the directors’ remuneration policy as set out in the Company’s annual report and accounts for the year ended December 31, 2025, which takes effect from the end of the annual general meeting, be approved.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

290,456,675

 

91.74%

 

26,150,725

 

8.26%

 

120,158,855

 

Resolution 6

That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

290,149,130

 

91.71%

 

26,223,920

 

8.29%

 

120,393,205

 

 

 

 

 

 

Resolution 7

That Justin Roberts be re-appointed as a director of the Company.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

295,886,535

 

93.77%

 

19,670,940

 

6.23%

 

121,208,780

 

Resolution 8

That Dr. Daniel Shames be re-appointed as a director of the Company.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

297,469,530

 

94.27%

 

18,085,670

 

5.73%

 

121,211,055

 

Resolution 9

That Marc Yoskowitz be re-appointed as a director of the Company.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

297,750,480

 

94.32%

 

17,929,525

 

5.68%

 

121,086,250

 

Resolution 10

 

That the Directors are authorized in accordance with section 551 of the Companies Act 2006 to allot shares in the Company and to grant rights to subscribe for or convert any security into shares in the Company up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 10 will expire on June 30, 2029 and would replace the existing authority granted at the general meeting of the Company held on May 22, 2023 to the extent not utilized at the date this Resolution is passed.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

254,728,730

 

80.54%

 

61,529,760

 

19.46%

 

120,507,765

 

Resolution 11

That, subject to Resolution 10 being passed, the Directors are authorized to allot shares for cash on a non-pre-emptive basis up to a maximum nominal amount of £3,591,354.73. The authority set out in Resolution 11 will expire on June 30, 2029.

 

Vote for

 

% of shares voted

 

Votes against

 

% of shares voted

 

Votes withheld

254,938,500

 

80.59%

 

61,391,160

 

19.41%

 

120,436,595

 

Based on the foregoing votes, the shareholders approved Resolutions 1, 2, 3, 4, 5, 6, 10 and 11 and re-elected each of Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.


Description of Exhibit

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

 

 

MEREO BIOPHARMA GROUP PLC

 

 

 

Date: May 14, 2026

By:

/s/ Charles Sermon

 

 

Name:

Charles Sermon

 

 

Title:

General Counsel

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Mereo BioPharma (MREO) shareholders approve at the 2026 AGM?

Shareholders approved all AGM resolutions, including the 2025 annual report and accounts, auditor re-appointment, remuneration report and policy, advisory executive compensation, re-election of three directors, and renewed authorities to allot shares and issue equity for cash on a non-pre-emptive basis until June 30, 2029.

How strong was support for Mereo BioPharma’s 2025 accounts and auditors?

Support was very high. The 2025 annual report and accounts were adopted with 311,388,645 votes for, or 98.29% of votes cast. PricewaterhouseCoopers LLP was re-appointed as auditors with 429,804,470 votes for, representing 98.59% of votes cast, and authority was granted for their remuneration.

How did Mereo BioPharma (MREO) shareholders vote on executive and director pay?

Shareholders approved the directors’ remuneration report with 93.35% support and the directors’ remuneration policy with 91.74% support. Advisory compensation for named executive officers also passed, receiving 290,149,130 votes for, or 91.71% of votes cast, indicating broad but not unanimous backing for pay practices.

Were Mereo BioPharma’s directors re-elected at the 2026 AGM?

Yes. Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz were each re-appointed as directors. Support was strong, with vote-for levels around 94% of votes cast for each director, confirming shareholder endorsement of the current board composition based on the disclosed results.

What new share issuance authority did Mereo BioPharma (MREO) receive?

Shareholders authorized directors to allot shares and grant subscription or conversion rights up to a maximum nominal amount of £3,591,354.73. They also approved issuing shares for cash on a non-pre-emptive basis up to the same nominal amount, with both authorities expiring June 30, 2029 and replacing earlier unused powers.

How many Mereo BioPharma shares were represented at the 2026 AGM vote?

A total of 436,766,255 ordinary shares entitled to vote were represented in person or by proxy. This high level of participation suggests broad shareholder engagement with the company’s 2026 Annual General Meeting and the governance and capital-authorization decisions presented there.

Filing Exhibits & Attachments

1 document

Other Documents